Artificial intelligence, or AI, has grown increasingly popular for its ability to process large sets of data. The term “AI” describes algorithms that can be taught to identify patterns or predict outcomes. If the algorithm is primed with a teaching set of data, then it can evaluate new sets of data based on the desired outcome. AI has been used to process patient data, biometric data, facial recognition data and geolocation data by various industries. However, it has fallen prey to criticism for potentially biased results and alleged invasion of user privacy.

Now, AI industry leaders are applying their technology to new issues raised by the novel coronavirus (COVID-19). Results show that AI can aid in combating COVID-19 and improve our response to future pandemics. However, to reach AI’s full potential in a health crisis, access to vast quantities of patient data is necessary. This article explores the benefits and risks of a regulatory framework allowing temporary access to patient data for the purpose of combating a global pandemic.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]